| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01048697 | Obesity|Tuberculosis | Drug: Ethambutol | Texas Tech University Health Sciences Center|National Center for Research Resources (NCRR)|University of Texas Southwestern Medical Center | Phase 4 | 2010-01-01 | 2013-01-23 |
| NCT01994460 | Pulmonary Tuberculosis Without Resistance to Rifampicin | Drug: Linezolid|Drug: Ethambutol | Seoul National University Hospital|Ministry of Health & Welfare, Korea|SMG-SNU Boramae Medical Center|Seoul National University Bundang Hospital|Pfizer | Phase 2 | 2014-01-01 | 2014-12-27 |
| NCT00002343 | Mycobacterium Avium-Intracellulare Infection|HIV Infections | Drug: Ethambutol hydrochloride|Drug: Rifabutin | Pharmacia|NIH AIDS Clinical Trials Information Service | Phase 4 | | 2005-06-23 |
| NCT00002140 | Mycobacterium Avium-intracellulare Infection|HIV Infections | Drug: Ethambutol hydrochloride|Drug: Clarithromycin|Drug: Azithromycin | Pfizer|NIH AIDS Clinical Trials Information Service | Phase 3 | | 2005-06-23 |
| NCT00002101 | Mycobacterium Avium-Intracellulare Infection|HIV Infections | Drug: Ethambutol hydrochloride|Drug: Clarithromycin|Drug: Rifabutin | Pharmacia|NIH AIDS Clinical Trials Information Service | Phase 3 | | 2005-06-23 |
| NCT00002331 | Mycobacterium Avium-intracellular Infection|HIV Infections | Drug: Ethambutol hydrochloride|Drug: Clarithromycin|Drug: Clofazimine | Abbott | | 1994-01-01 | 2015-01-15 |
| NCT01866579 | Primary Lung Tuberculosis | | Yonsei University | | 2013-05-01 | 2014-05-19 |
| NCT00864383 | Pulmonary Tuberculosis | Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Global Alliance for TB Drug Development|European and Developing Countries Clinical Trials Partnership (EDCTP)|University College, London|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi | Phase 3 | 2008-01-01 | 2017-02-15 |
| NCT00000641 | Mycobacterium Avium-intracellulare Infection|HIV Infections | Drug: Ciprofloxacin hydrochloride|Drug: Ethambutol hydrochloride|Drug: Amikacin sulfate|Drug: Azithromycin|Drug: Rifampin|Drug: Clofazimine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | | 2012-03-29 |
| NCT01399788 | Healthy Volunteers | Drug: Myrin P Forte|Drug: Single drug references | Pfizer | Phase 1 | 2011-07-01 | 2012-05-09 |
| NCT00367913 | Pulmonary Diseases | Drug: Addition of clarithromycin to rifampicin and ethambutol|Drug: Addition of Ciprofloxacin to rifampicin and ethambutol|Biological: Vaccination with M.vaccae | British Thoracic Society | Phase 4 | 1995-03-01 | 2006-08-21 |
| NCT02114684 | Recurrent Tuberculosis | Drug: moxifloxacin | Centre for the AIDS Programme of Research in South Africa | Phase 1|Phase 2 | 2013-11-01 | 2017-01-31 |
| NCT01782950 | AIDS With Tuberculosis | Drug: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide | Makerere University | Phase 4 | 2013-02-01 | 2015-04-10 |
| NCT00144417 | Tuberculosis | Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Drug: isoniazid | Centers for Disease Control and Prevention|Global Alliance for TB Drug Development|Bayer | Phase 2 | 2006-02-01 | 2011-08-02 |
| NCT01169038 | Pulmonary Sarcoidosis|Lung Function | Drug: levaquin; ethambutol; rifampin and azithromycin. | Vanderbilt University | Phase 1 | 2010-07-01 | 2012-10-26 |
| NCT00351702 | Human Immunodeficiency Virus|Tuberculosis | Drug: Isoniazid with Ethambutol | Tuberculosis Research Centre, India|United States Agency for International Development (USAID) | Phase 3 | 2001-02-01 | 2016-06-06 |
| NCT00023374 | Tuberculosis | Drug: Rifampin|Drug: Pyrazinamide|Drug: Ethambutol|Drug: REZ | Centers for Disease Control and Prevention|VA Office of Research and Development | | 2000-08-01 | 2011-08-02 |
| NCT00140309 | Tuberculosis, Pulmonary | Drug: moxifloxacin (with isoniazid, rifampin, pyrazinamide) | Centers for Disease Control and Prevention | Phase 2 | 2003-07-01 | 2007-03-16 |
| NCT01154959 | Pulmonary Tuberculosis | Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol | Tuberculosis Research Centre, India|National Institutes of Health (NIH) | Phase 3 | 2010-02-01 | 2011-06-15 |
| NCT00698334 | HIV Infections|Acquired Immunodeficiency Syndrome|Tuberculosis | Drug: INH, Rifampicin, Ethambutol and Pyrazinamide|Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | All India Institute of Medical Sciences, New Delhi|Ministry of Health & Family Welfare, India | Phase 3 | 2006-04-01 | 2011-11-05 |
| NCT00933790 | HIV Infection|Pulmonary TB | Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin) | Tuberculosis Research Centre, India | Phase 3 | 2009-09-01 | 2016-03-21 |
| NCT00728507 | Tuberculosis | Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Johns Hopkins University|Universidade Federal do Rio de Janeiro|Municipal Health Secretary of Rio de Janeiro|Helio Fraga Reference Center, Fiocruz | Phase 2 | 2009-11-01 | 2013-04-01 |
| NCT01392911 | Pulmonary Tuberculosis (TB) | Drug: Rifampicin | Radboud University|European and Developing Countries Clinical Trials Partnership (EDCTP)|Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.|University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL | Phase 2 | 2011-06-01 | 2014-06-06 |
| NCT00376012 | Tuberculosis|Human Immunodeficiency Virus Infections | Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) | Tuberculosis Research Centre, India | Phase 3 | 2001-02-01 | 2008-06-10 |
| NCT00130247 | Tuberculosis | Drug: Pyrazinamide|Drug: Rifampin|Drug: Isoniazid|Drug: Ethambutol | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2002-04-01 | 2013-01-31 |
